Publication at First Faculty of Medicine |
2019
Abstract
Multiple sclerosis (MS) represents severe autoimmune disease of the central nervous system, typically afflicting young people in productive age. Currently a large portfolio of modern drugs is available.
These drugs are fundamentally modifying disease course, however we are still searching for optimal treatment effectivity and prognostic markers in an individual patient. The article summarizes all markers used in evaluation of treatment response and disease progression including composite marker NEDA (No Evidence of Disease Activity).
NEDA corresponds to absence of clinical as well as radiological disease activity and is one of the major goals in current MS treatment